Cancer
Malignant Gastric Neoplasm
CI-CAN-00001130Explore in graph →
Top-level650 active trials4 approved drugs55 evidence items
Loading cancer entity…
Cancer
CI-CAN-00001130Explore in graph →
Clinical trials
2,844 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (232)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05000554 | The Safety and Efficacy of PD-1 Monoantrapical Chemotherapy in the Treatment of Local Advanced Stomach Cancer | unknown | Phase 2 | 30 | The First Hospital of Jilin UniversityOTHER | 1 | Aug 11, 2021 | clinicaltrials |
| NCT04973475 | Indocyanine Green Tracer Using in Laparoscopic Distal Gastrectomy for Early Gastric Cancer | unknown | Phase 2 | 180 | Fujian Medical UniversityOTHER | 1 | Jul 22, 2021 | clinicaltrials |
| NCT03648879 | Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer Syndrome | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jul 12, 2021 | clinicaltrials |
| NCT04948125 | Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma | unknown | Phase 2 | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 1, 2021 | clinicaltrials |
| NCT04934618 | A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer | unknown | Phase 2 | 85 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT04907864 | Effect of Multi-modal Intervention Care on Cachexia in Patients With Advanced Cancer Compared to Conventional Management (MIRACLE)(MIRACLE) | unknown | Phase 2 | 112 | Kil Yeon LeeOTHER | 1 | Jun 1, 2021 | clinicaltrials |
| NCT04781686 | Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer | unknown | Phase 2 | 35 | Zhou FuxiangOTHER | 1 | May 17, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT02564367 | Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction(S-1 adjuvant) | completed | Phase 1 / Phase 2 | 30 | AIO-Studien-gGmbHOTHER | 1 | Apr 29, 2021 | clinicaltrials |
| NCT02845908 | POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC | completed | Phase 2 | 90 | Fujian Cancer HospitalOTHER_GOV | 1 | Apr 23, 2021 | clinicaltrials |
| NCT04442984 | FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III)(IRIGA) | unknown | Phase 2 | 326 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Apr 13, 2021 | clinicaltrials |
| NCT02901301 | Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer | unknown | Phase 1 / Phase 2 | 41 | Yonsei UniversityOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT04826107 | Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer | unknown | Phase 2 | 196 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Apr 1, 2021 | clinicaltrials |
| NCT02128243 | Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer(MATEO) | completed | Phase 2 | 242 | AIO-Studien-gGmbHOTHER | 1 | Mar 26, 2021 | clinicaltrials |
| NCT04563975 | Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer | unknown | Phase 2 | 54 | Tao ZhangOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT04797923 | A Phase II Study of Conversion Surgery After IP Paclitaxel With XELOX Chemotherapy in AGC With Peritoneal Dissemination | unknown | Phase 2 | 43 | Gangnam Severance HospitalOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04792515 | Camrelizumab Combined With SOX and/or Apatinib for Locally Advanced Gastric Cancer(CCWSA/OAFLAG) | unknown | Phase 2 | 67 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT04777162 | Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer | unknown | Phase 2 | 40 | Peking UniversityOTHER | 1 | Mar 4, 2021 | clinicaltrials |
| NCT04781413 | Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer | unknown | Phase 1 / Phase 2 | 38 | Ruijin HospitalOTHER | 1 | Mar 4, 2021 | clinicaltrials |
| NCT03322969 | Receiving Modified Chemotherapy Followed With Radical Resection After Neoadjuvant Chemotherapy | unknown | Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT00064259 | A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 17, 2021 | clinicaltrials |
| NCT03941626 | Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies | unknown | Phase 1 / Phase 2 | 50 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT00061932 | Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Feb 2, 2021 | clinicaltrials |
| NCT03083613 | Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma | completed | Phase 2 | 41 | Chinese Academy of Medical SciencesOTHER | 1 | Feb 1, 2021 | clinicaltrials |
| NCT01359397 | Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer(B-DOCT) | unknown | Phase 2 | — | The Netherlands Cancer InstituteOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT01702558 | A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)(TRAXHER2) | terminated | Phase 2 | 182 | Hoffmann-La RocheINDUSTRY | 12 | Jan 22, 2021 | clinicaltrials |
| NCT04136600 | EGFR Monoclonal Antibody for Advanced Gastric Cancer | unknown | Phase 2 | 100 | Shanghai Changzheng HospitalOTHER | 1 | Dec 30, 2020 | clinicaltrials |
| NCT04677673 | Neoadjuvant Chemotherapy Plus Surgery Versus Surgery First For Elderly Gastric Cancer Patients(RJGC-Senile) | not yet recruiting | Phase 2 / Phase 3 | 232 | BIRENDRA KUMAR SAHOTHER | 0 | Dec 21, 2020 | clinicaltrials |
| NCT02082210 | A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | completed | Phase 1 / Phase 2 | 97 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT01084330 | Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer | completed | Phase 2 | 68 | Novartis PharmaceuticalsINDUSTRY | 14 | Dec 10, 2020 | clinicaltrials |
| NCT01402401 | Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients | terminated | Phase 2 | 21 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 10, 2020 | clinicaltrials |
| NCT03154983 | The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer | unknown | Phase 2 | 48 | Zhou FuxiangOTHER | 1 | Dec 9, 2020 | clinicaltrials |
| NCT00952003 | Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients | completed | Phase 2 | 40 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Nov 30, 2020 | clinicaltrials |
| NCT04631757 | Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | unknown | Phase 2 | 33 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Nov 17, 2020 | clinicaltrials |
| NCT03825861 | Neoadjuvant FOLFIRINOX in the Treatment of Locally Advanced Gastric Cancer(FOLFIRINOX) | recruiting | Phase 2 | 27 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Nov 10, 2020 | clinicaltrials |
| NCT04338438 | Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer | completed | Phase 2 | 37 | Beijing Friendship HospitalOTHER | 0 | Nov 10, 2020 | clinicaltrials |
| NCT00003862 | Chemotherapy and Radiation Therapy in Treating Patients With Stomach Cancer | completed | Phase 2 | — | Radiation Therapy Oncology GroupNETWORK | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03554395 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Gastric Cancer | withdrawn | Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT04567069 | Safety and Efficacy Study for MG-7-DC Vaccine in Gastric Cancer Treatment | unknown | Phase 1 / Phase 2 | 45 | The Second Hospital of Shandong UniversityOTHER | 1 | Sep 28, 2020 | clinicaltrials |
| NCT04555304 | Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy | unknown | Phase 2 | 81 | Chengdu Kanghong Biotech Co., Ltd.INDUSTRY | 0 | Sep 18, 2020 | clinicaltrials |
| NCT04358341 | Pegliposomal Doxorubicin and 5-fluorouracil as Second Line Therapy for Metastatic Gastric Cancer | unknown | Phase 2 | 136 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Aug 24, 2020 | clinicaltrials |
| NCT02581462 | FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer(PETRARCA) | completed | Phase 2 / Phase 3 | 81 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Aug 11, 2020 | clinicaltrials |
| NCT04503967 | Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer(OASIS) | unknown | Phase 2 | 48 | Shanghai Zhongshan HospitalOTHER | 0 | Aug 7, 2020 | clinicaltrials |
| NCT00985192 | Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer | completed | Phase 2 | 49 | Translational Oncology Research InternationalOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT00003748 | Irinotecan in Treating Patients With Esophageal or Stomach Cancer | completed | Phase 2 | 40 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT00020761 | Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach | completed | Phase 2 | 51 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT02443883 | A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer | completed | Phase 2 | 164 | Eli Lilly and CompanyINDUSTRY | 12 | Jun 29, 2020 | clinicaltrials |
| NCT02514551 | A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer | completed | Phase 2 | 245 | Eli Lilly and CompanyINDUSTRY | 11 | Jun 17, 2020 | clinicaltrials |
| NCT04410887 | Neoadjuvant Chemotherapy With PISOXO for Locally-invaded-gastric Cancer (LIGC) | unknown | Phase 1 / Phase 2 | 30 | Ruijin HospitalOTHER | 1 | Jun 1, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Aug 11, 2021source: clinicaltrials